Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Centro de Investigação em Saúde de Manhiça (CISM)
Street 1: Rua 12
Street 2: Cambeve
City: Manhiça
Province: Maputo
Post Code: 1929
Country: Mozambique
Phone: +258 866575707
Email: eusebio.macete@manhica.net
Web Site: http://www.manhica.org

Focal Point Contact Information

Salutation: Dr
First Name: Alberto
Last Name: Garcia-Basteiro
Title: Dr
Email: alberto.garcia-basteiro@manhica.net
Phone: +258 866575707

Alternate Focal Point Contact Information

Salutation: Dr
First Name: Eusebio
Last Name: Macete
Title: Dr
Email: eusebio.macete@manhica.net
Phone: +258 823041570

General Information

Board Constituency: Foundation
Organization Type - Primary: Foundation
Organization Type - Secondary: Private Foundation
Is your organization legally registered in your country: Yes
Organization Reach: International
Organization Description:
The Manhiça Health Research Centre (Centro de Investigação em Saúde de Manhiça, CISM) was created in 1996 to promote and conduct biomedical research in priority health areas. Since its creation, the Centre has been developing its activities under a bilateral cooperation programme between the Governments of Mozambique and Spain, and with the support of the Hospital Clínic / Universitat de Barcelona (through the Fundació Clínic per a la Recerca Biomèdica).

1. MISSION
To conduct biomedical research in health priority areas to protect and improve the population’s health
Our vision is to be a center of excellence in biomedical research that generates evidence to guide public health policy countries in the world

2. TB is one of the most important public health issues in the country and as such, we try to come up with new tools to fight TB.

3. WE conduct clinical trials in the fields of drug and vaccine development as well as participate in studies of new diagnostics for TB. We also conduct epidemiological research to better characterize and quantify TB in the district of Manhiça, southern Mozambique.
 
Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 6 - 10
Number of part-time staff who are directly involved with TB: 1 - 5
Number of volunteers who are directly involved with TB: 0
 
What is your organization's annual budget (USD) dedicated to TB? $1 MIL-$10 MIL
How did you hear about the Stop TB Partnership: Stop TB communications
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
We conduct biomedical research which provides operational data that can be used by the NTP for policy making.
 

Geographical Reach

Which country is your headquarters located in: Mozambique
Which WHO region is the main focus of your work: African
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Mozambique

Specializations

Advocacy
Research and Development

Specializations in Countries

Research and Development Mozambique

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
We conduct drug resistance surveys to monitor drug resistance in our district

TB-HIV:
We do epidemiological studies on TB HIV coinfected patients. 75% of our patients are HIV co infected

Laboratory Strengthening:
We have participated in EDCTP projects which aimed at strenghtening and equipping our laboratory to offer better TB diagnosis services

New Diagnostics:
We participate in studies to come up with improved diagnostic tests for TB diagnosis

New TB Drugs:
We have participated and participate in different drug clinical trials

New TB Vaccines:
We have participated in AERAS 402 vaccine trial in 2010-2013.

Research:
Any of the above fields is tackled from the research point of view. Research is our main focus.

Declaration

Declaration of interests:
We have no conflicts of interest

Application date: August 3, 2016
Last updated: August 17, 2016